PE20170916A1 - COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING BMP6 - Google Patents
COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING BMP6Info
- Publication number
- PE20170916A1 PE20170916A1 PE2017001091A PE2017001091A PE20170916A1 PE 20170916 A1 PE20170916 A1 PE 20170916A1 PE 2017001091 A PE2017001091 A PE 2017001091A PE 2017001091 A PE2017001091 A PE 2017001091A PE 20170916 A1 PE20170916 A1 PE 20170916A1
- Authority
- PE
- Peru
- Prior art keywords
- sequence
- amino acids
- seq
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SE REFIERE A UN ANTICUERPO AISLADO O FRAGMENTO DEL MISMO DE UNION AL ANTIGENO QUE SE UNE A BMP6 HUMANA QUE COMPRENDE: A) LAS SIGUIENTES TRES REGIONES DETERMINANTES DE COMPLEMENTARIEDAD DE CADENA PESADA (HCDR) i) HCDR1 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 69, ii) HCDR2 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 70, Y iii) HCDR3 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 71; Y B) LAS SIGUIENTES TRES REGIONES DETERMINANTES DE COMPLEMENTARIEDAD DE CADENA LIGERA (LCDR) i) LCDR1 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 79, ii) LCDR2 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 80, Y iii) LCDR3 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 81. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA, UN POLINUCLEOTIDO, UN VECTOR DE EXPRESION Y A UNA CELULA HUESPED. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DE LA ANEMIA, CANCERIT REFERS TO AN ISOLATED ANTIBODY OR FRAGMENT OF THE SAME BINDING TO THE ANTIGEN THAT IS BINDING TO HUMAN BMP6, INCLUDING: A) THE FOLLOWING THREE DETERMINING REGIONS OF HEAVY CHAIN COMPLEMENTARITY (HCDR) i) HCDR1 SEQUENCE OF IDENTIFICATION NO: 69, ii) HCDR2 THAT INCLUDES THE SEQUENCE OF AMINO ACIDS OF SEQ ID NO: 70, AND iii) HCDR3 THAT INCLUDES THE SEQUENCE OF AMINO ACIDS OF SEQ ID NO: 71; AND B) THE FOLLOWING THREE DETERMINING REGIONS OF LIGHT CHAIN COMPLEMENTARITY (LCDR) i) LCDR1 THAT INCLUDES THE SEQUENCE OF AMINO ACIDS OF SEQ ID NO: 79, ii) LCDR2 THAT INCLUDES THE SEQUENCE OF AMINO ACIDS OF SEC ID NO: 80, AND iii) LCDR3 INCLUDING THE SEQUENCE OF AMINO ACIDS OF SEQ ID NO: 81. ALSO REFERS TO A PHARMACEUTICAL COMPOSITION, A POLYNUCLEOTIDE, A VECTOR OF EXPRESSION AND A HOST CELL. SAID ANTIBODY IS USEFUL IN THE TREATMENT OF ANEMIA, CANCER
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462094716P | 2014-12-19 | 2014-12-19 | |
US201562181803P | 2015-06-19 | 2015-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20170916A1 true PE20170916A1 (en) | 2017-07-12 |
Family
ID=55069038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017001091A PE20170916A1 (en) | 2014-12-19 | 2015-12-18 | COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING BMP6 |
Country Status (26)
Country | Link |
---|---|
US (3) | US9862764B2 (en) |
EP (1) | EP3233913B1 (en) |
JP (2) | JP6802796B2 (en) |
KR (1) | KR20170089010A (en) |
CN (1) | CN107531783B (en) |
AU (2) | AU2015365373C1 (en) |
BR (1) | BR112017012954A2 (en) |
CA (1) | CA2970869A1 (en) |
CL (1) | CL2017001461A1 (en) |
CO (1) | CO2017005941A2 (en) |
CR (1) | CR20170262A (en) |
EC (1) | ECSP17045736A (en) |
ES (1) | ES2957214T3 (en) |
GT (1) | GT201700131A (en) |
IL (1) | IL252966B (en) |
JO (1) | JO3791B1 (en) |
MX (1) | MX2017008191A (en) |
MY (1) | MY183779A (en) |
PE (1) | PE20170916A1 (en) |
PH (1) | PH12017501077A1 (en) |
SG (1) | SG11201704634SA (en) |
TN (1) | TN2017000242A1 (en) |
TW (1) | TWI714545B (en) |
UY (1) | UY36449A (en) |
WO (1) | WO2016098079A2 (en) |
ZA (1) | ZA201703897B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY36449A (en) * | 2014-12-19 | 2016-07-29 | Novartis Ag | COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6 |
SG10201913062SA (en) | 2015-07-31 | 2020-03-30 | Medimmune Ltd | Methods for treating hepcidin-mediated disorders |
GB2550114A (en) | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
EP3471759A1 (en) * | 2016-06-15 | 2019-04-24 | Novartis AG | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6) |
AU2018214554C1 (en) | 2017-02-01 | 2022-12-15 | Novo Nordisk A/S | Treatment of diuretic resistance |
EP3415527A1 (en) | 2017-06-14 | 2018-12-19 | Technische Universität Dresden | Use of the extracellular domain of the transferrin receptor 2 for diagnosis and treatment of primary and secondary sclerosing diseases |
JP7395479B2 (en) | 2018-01-05 | 2023-12-11 | ノヴォ ノルディスク アー/エス | Methods of treating IL-6-mediated inflammation without immunosuppression |
US20210214456A1 (en) | 2018-06-13 | 2021-07-15 | Kymab Limited | Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone |
GB201815629D0 (en) * | 2018-09-25 | 2018-11-07 | Kymab Ltd | Antagonists |
AU2019368287A1 (en) | 2018-10-23 | 2021-06-10 | Scholar Rock, Inc. | RGMc-selective inhibitors and use thereof |
MA56203A (en) * | 2019-06-12 | 2022-04-20 | Regeneron Pharma | HUMAN ANTIBODIES AGAINST BONE MORPHOGENETIC PROTEIN 6 |
AU2021205440A1 (en) | 2020-01-11 | 2022-09-01 | Scholar Rock,Inc. | TGF-beta inhibitors and use thereof |
US20220401445A1 (en) * | 2020-04-30 | 2022-12-22 | Keros Therapeutics, Inc. | Methods of using alk2 inhibitors |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5187076A (en) | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | Modifications of or for denatured antibodies |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
KR900005995A (en) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | Modified Interleukin-2 and Method of Making the Same |
WO1990006952A1 (en) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
FR2650598B1 (en) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION |
WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
DK0463151T3 (en) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Generation of xenogenic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
DE69133476T2 (en) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgenic mice capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5242813A (en) | 1990-10-12 | 1993-09-07 | The United States Of America As Represented By The Department Of Health And Human Services | Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors |
ATE145428T1 (en) | 1990-12-14 | 1996-12-15 | Cell Genesys Inc | CHIMERIC CHAINS FOR TRANSDUCTION OF RECEPTOR-CONNECTED SIGNALING PATHWAYS |
PT528767E (en) | 1991-08-21 | 2000-06-30 | Novartis Ag | ANTIBODY DERIVATIVES |
ES2227512T3 (en) | 1991-12-02 | 2005-04-01 | Medical Research Council | PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO. |
ES2202310T3 (en) | 1991-12-13 | 2004-04-01 | Xoma Corporation | METHODS AND MATERIALS FOR THE PREPARATION OF VARIABLE DOMAINS OF MODIFIED ANTIBODIES AND THEIR THERAPEUTIC USES. |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
FR2686901A1 (en) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | NOVEL ANTITHROMBOTIC POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5610021A (en) | 1992-02-21 | 1997-03-11 | Creative Biomolecules, Inc. | Compositions and methods for identification and use of soluble complex forms of osteogenic proteins |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
DE69330523T4 (en) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | IMMUNOGLOBULINE WITHOUT LIGHT CHAINS |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
SE9400088D0 (en) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
JPH09512910A (en) | 1994-05-04 | 1997-12-22 | マウント・サイナイ・ホスピタル・コーポレイション | TGF-β superfamily cytokine modulators and assay methods thereof |
WO1996004388A1 (en) | 1994-07-29 | 1996-02-15 | Smithkline Beecham Plc | Novel compounds |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
AU6094696A (en) | 1995-06-05 | 1996-12-24 | Bionebraska, Inc. | Lead binding polypeptides and nucleotides coding therefor |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
ATE282092T1 (en) | 1997-06-11 | 2004-11-15 | Borean Pharma As | TRIMERIZING MODULE |
DK0985039T3 (en) | 1997-06-12 | 2008-06-09 | Novartis Int Pharm Ltd | Artificial antibody polypeptides |
DE19742706B4 (en) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | lipocalin muteins |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DE69942021D1 (en) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | GLYCOSYLATION ENGINEERING OF ANTIBODIES TO IMPROVE ANTIBODY-DEPENDENT CELL-EMITTED CYTOTOXICITY |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
PL220113B1 (en) | 1999-01-15 | 2015-08-31 | Genentech Inc | Variant of parent polypeptide comprising the Fc region, polypeptide comprising a variant of the Fc region with altered binding affinity of Fc gamma receptor (FcγR), a polypeptide comprising the variant of Fc region with altered binding affinity of neonatal Fc receptor (FcRn), a composition, isolated nucleic acid, vector, host cell, method for preparing the polypeptide variant, the use of the polypeptide variant and method for preparing a the Fc region variant |
EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
DE19932688B4 (en) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design of beta-sheet proteins of gamma-II-crystalline antibody-like |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
CA2405701A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
EP1421203A4 (en) | 2001-05-17 | 2005-06-01 | Diversa Corp | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
ATE395413T1 (en) | 2001-12-03 | 2008-05-15 | Amgen Fremont Inc | ANTIBODIES CATEGORIZATION BASED ON BINDING PROPERTIES |
US20030157579A1 (en) | 2002-02-14 | 2003-08-21 | Kalobios, Inc. | Molecular sensors activated by disinhibition |
US7335478B2 (en) | 2002-04-18 | 2008-02-26 | Kalobios Pharmaceuticals, Inc. | Reactivation-based molecular interaction sensors |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
US7816497B2 (en) | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
US20050008625A1 (en) | 2003-02-13 | 2005-01-13 | Kalobios, Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
DE10324447A1 (en) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generation of artificial binding proteins based on ubiquitin |
EP1761561B1 (en) | 2004-01-20 | 2015-08-26 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
US20060243522A1 (en) | 2005-02-14 | 2006-11-02 | Hart Kelly F | Portable stepping device |
WO2006088972A2 (en) | 2005-02-16 | 2006-08-24 | The General Hospital Corporation | Use of modulatirs of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
PE20071101A1 (en) | 2005-08-31 | 2007-12-21 | Amgen Inc | POLYPEPTIDES AND ANTIBODIES |
KR101510753B1 (en) | 2006-06-07 | 2015-04-10 | 바이오얼라이언스 씨.브이. | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
EP2270229A1 (en) | 2006-09-12 | 2011-01-05 | The General Hospital Corporation | Inhibitors of bone morphogenetic protein (BMP) signalling for therapeutical purposes |
CA2700831A1 (en) | 2007-09-28 | 2009-04-09 | Stryker Corporation | Methods for detecting neutralizing antibodies for bone morphogenetic proteins |
CN102215869B (en) | 2008-11-13 | 2015-05-13 | 通用医疗公司 | Methods and compositions for regulating iron homeostasis by modulation BMP-6 |
US20140086919A1 (en) | 2012-09-24 | 2014-03-27 | Herbert Y. Lin | Methods and compositons for regulating iron homeostasis by modulation of bmp-6 |
US20110070242A1 (en) | 2009-09-01 | 2011-03-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for Diagnosing and Treating Iron Dysregulation |
AU2012251919B2 (en) | 2011-01-19 | 2016-12-15 | Ferrumax Pharmaceuticals, Inc. | Compositions for regulating iron homeostasis and methods of using same |
AU2012253204A1 (en) | 2011-05-06 | 2013-04-18 | Women's And Children's Health Research Institute Inc | Method of treatment and prophylaxis of pathologies of the bone |
EP2868667B1 (en) | 2012-07-02 | 2019-01-30 | Kyowa Hakko Kirin Co., Ltd. | Therapeutic agent for anemia including renal anemia and cancer-induced anemia which contains anti-bmp9 antibody as active ingredient |
KR101707760B1 (en) | 2012-12-07 | 2017-02-16 | 보벤 프로퍼티즈 게엠베하 | Rotor blade trailing edge |
AR093620A1 (en) | 2012-12-17 | 2015-06-10 | Lilly Co Eli | BMP-6 ANTIBODIES |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
UY36449A (en) * | 2014-12-19 | 2016-07-29 | Novartis Ag | COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6 |
-
2015
- 2015-12-16 UY UY0001036449A patent/UY36449A/en not_active Application Discontinuation
- 2015-12-17 JO JOP/2015/0325A patent/JO3791B1/en active
- 2015-12-18 ES ES15819883T patent/ES2957214T3/en active Active
- 2015-12-18 TW TW104142804A patent/TWI714545B/en active
- 2015-12-18 CR CR20170262A patent/CR20170262A/en unknown
- 2015-12-18 PE PE2017001091A patent/PE20170916A1/en unknown
- 2015-12-18 WO PCT/IB2015/059797 patent/WO2016098079A2/en active Application Filing
- 2015-12-18 CA CA2970869A patent/CA2970869A1/en active Pending
- 2015-12-18 BR BR112017012954-0A patent/BR112017012954A2/en active Search and Examination
- 2015-12-18 CN CN201580076468.1A patent/CN107531783B/en active Active
- 2015-12-18 MY MYPI2017702099A patent/MY183779A/en unknown
- 2015-12-18 MX MX2017008191A patent/MX2017008191A/en unknown
- 2015-12-18 AU AU2015365373A patent/AU2015365373C1/en active Active
- 2015-12-18 EP EP15819883.8A patent/EP3233913B1/en active Active
- 2015-12-18 SG SG11201704634SA patent/SG11201704634SA/en unknown
- 2015-12-18 TN TN2017000242A patent/TN2017000242A1/en unknown
- 2015-12-18 US US14/974,318 patent/US9862764B2/en active Active
- 2015-12-18 JP JP2017532601A patent/JP6802796B2/en active Active
- 2015-12-18 KR KR1020177019566A patent/KR20170089010A/en active IP Right Grant
-
2017
- 2017-06-07 ZA ZA2017/03897A patent/ZA201703897B/en unknown
- 2017-06-08 PH PH12017501077A patent/PH12017501077A1/en unknown
- 2017-06-08 CL CL2017001461A patent/CL2017001461A1/en unknown
- 2017-06-15 CO CONC2017/0005941A patent/CO2017005941A2/en unknown
- 2017-06-16 GT GT201700131A patent/GT201700131A/en unknown
- 2017-06-18 IL IL252966A patent/IL252966B/en active IP Right Grant
- 2017-07-16 EC ECIEPI201745736A patent/ECSP17045736A/en unknown
- 2017-11-20 US US15/818,090 patent/US10683346B2/en active Active
-
2019
- 2019-05-14 AU AU2019203368A patent/AU2019203368A1/en not_active Abandoned
-
2020
- 2020-05-04 US US16/865,723 patent/US11530261B2/en active Active
- 2020-06-30 JP JP2020112233A patent/JP2020182467A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20170916A1 (en) | COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING BMP6 | |
PE20181326A1 (en) | ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND ITS USES | |
PE20190630A1 (en) | ANTI-TIM-3 ANTIBODIES | |
PE20181921A1 (en) | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS | |
PE20210132A1 (en) | ANTI-CD3 ANTIBODIES AND USES OF THEM | |
AR110017A1 (en) | PD-1 ANTIBODIES AND USES OF THESE | |
CL2019001926A1 (en) | Anti-tigit antibodies and antigen-binding fragments; pharmaceutical composition comprising them; polynenucleotide encoding said antibody; vector comprising them, host cell; method of producing said antibody or antigen-binding fragment thereof; and use in the treatment of cancer. (Divisional Application 310-2017). | |
PE20141151A1 (en) | CD27L ANTIGEN BINDING PROTEINS | |
PE20200294A1 (en) | ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND METHODS OF USE | |
ES2687282T3 (en) | ANTI-CD134 (OX40) humanized antibodies and their uses | |
PE20221580A1 (en) | THERAPEUTIC ANTIBODIES AND THEIR USES | |
PE20181090A1 (en) | IMMUNE MODULATION AND TREATMENT OF SOLID TUMORS WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 | |
PE20141147A1 (en) | ANTIBODIES TO PCSK9 AND USES OF THEM | |
MX2019007848A (en) | Anti-pd-1 antibodies and uses thereof. | |
PE20180604A1 (en) | PD-L1 ANTIBODIES (JOINING LINK 1 OF PROGRAMMED CELL DEATH 1 HUMAN) | |
PE20200011A1 (en) | ANTI-PEPTIDE BETA AMYLOID N3pGlu ANTIBODIES AND THEIR USES | |
PE20170665A1 (en) | HUMANIZED ANTI-TAU ANTIBODIES | |
PE20171654A1 (en) | COMPOSITIONS AND METHODS USED TO INCREASE IMMUNE RESPONSE AND IN CANCER THERAPY | |
NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
PE20130817A1 (en) | PEPTIDE ANTIBODIES BETA AMYLOID ANTI-N3PGLU AND USES THEREOF | |
AR102239A1 (en) | ANTI-OX40 HUMANIZED ANTIBODIES AND THEIR USES | |
PE20212088A1 (en) | ANTI-TAU ANTIBODIES AND THEIR USE | |
CO6230999A2 (en) | ANTI-SCLEROSTINE ANTIBODY | |
AR103713A1 (en) | ANTIBODIES AGAINST TAU AND ITS USES | |
PE20150159A1 (en) | COMPOSITIONS AND METHODS FOR ANTIBODIES ACTING ON THE P FACTOR |